Get the latest industry news first by subscribing to our newsletter.
An agreement between one of the leading corporations to expand a vaccine opposed to the virus for which Covid-19 has signed an agreement to potentially supply more than one hundred million doses to Europe.
Modern, in Cambridge, Massachusetts, said Monday that it had reached an agreement with the European Commission to supply 80 million doses of mRNA-1273, its messenger RNA vaccine opposite SARS-CoV-2. Member States can also get another 80 million doses, for a total of 160 million. The vaccine is given in two doses: a fundamental injection followed by a booster injection 29 days later.
“European components, investors and citizens have been part of Moderna since the company’s inception and have played a vital role in Moderna’s progress,” Moderna’s general manager Stephane Bancel said in a statement. “We are expanding our outdoor production capacity outside the United States with our strategic components, Lonza in Switzerland and Rovi in Spain, to be able to cope with this global fitness emergency with a widely available vaccine once its use is approved. “
Lonza and Rovi are contracted brands with which Moderna has partnered to produce vaccine supplies. The company said it will expand to produce about 500 million doses a year and potentially up to 1 billion starting next year.
The vaccine is recently undergoing a phase III trial of 30,000 healthy adults, which is expected to be completed next month. The test has 99 sites, all in Etats-Unis. Two weeks ago, the company said it had reached a settlement worth more than $1.5 billion to supply a hundred million doses of mRN-1273, with the option of supplying another $400 million – to the federal government. Government.
Other vaccine corporations have agreements with governments in the United States, Europe and Japan. French drug manufacturer Sanofi and its UK-based partner GlaxoSmithKline have an agreement to supply one hundred million doses of their vaccine, while Pfizer and Germany’s BioNTech have reached an agreement for theirs, which, like mRNA-1273, also targets messenger RNA.
Photo: Otherimas, Getty Images
biopharmaceuticals nl, Cambridge, coronavirus, COVID-19, European Commission, Massachusetts, Modern, MNR-1273, SARS-CoV-2, vaccines
Get the latest industry news first by subscribing to our newsletter.
Our sites